← Tonix Pharmaceuticals Holding Corp. (TNXP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Tonix Pharmaceuticals Holding Corp. (TNXP)
Pharmaceutical Preparations · market cap $174M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
9
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Tonix Pharmaceuticals (TNXP) is a ~$200M market cap CNS-focused pharmaceutical company with 81 employees and a lead asset, TNX-102 SL, in Phase 3 trials for fibromyalgia and PTSD. The company holds $185.5M in cash against a ~13-month runway, with a pipeline that also includes Phase 2 assets in depression, tension-type headache, and chronic migraine. No recent clinical catalysts have been disclosed; the next scheduled event is an August 2026 earnings release.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-01-01Partnershipimp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TNX-102 SL Tablet, 5.6 mg | Phase 3 | Fibromyalgia |
| TNX-102 SL Tablet, 2.8mg | Phase 3 | Fibromyalgia |
| TNX-102 SL Tablet 2.8 mg | Phase 3 | Primary Fibromyalgia |
| TNX-102 SL | Phase 3 | Primary Fibromyalgia |
| TNX-102 SL 5.6 mg | Phase 3 | PTSD |
| TNX-601 ER | Phase 2 | Depression |
| TNX-201 | Phase 2 | Tension-Type Headache |
| TNX-102 SL 2.8mg | Phase 3 | Primary Fibromyalgia |
| TNX-1900 | Phase 2 | Chronic Migraine |
Price & technical context
3-month
-25.2%
6-month
-32.5%
12-month
-61.8%
52-wk range
$9.23–$24.72
vs 50-day MA
-21.0%
vs 200-day MA
-31.9%
Realized vol
69.8%
Max drawdown
-87.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TNXP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.